The content on this site is intended for healthcare professionals only
Prof Giaccone presents about immunotherapy in NSCLC at the Future Horizons in Lung Cancer meeting.
Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Uncommon genetic aberrations NTRK, RET, NRG
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Updates on lung cancer from WCLC and ESMO 2023
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
